Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 7/20 | 0.52 |
| ▸ | GNRHR | P30968 | 1/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.50 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31058451 | 0.96 | CXCR4 (0.52) | CXCR4CAPN1CTSBKISS1RCXCL8 | |
| SCHEMBL30523243 | 0.93 | CXCR4 (0.54) | CXCR4GNRHRCAPN1CTSBKISS1R | |
| SCHEMBL32677767 | 0.91 | CAPN1 (0.58) | CXCR4CAPN1CTSB | |
| SCHEMBL32677770 | 0.91 | CAPN1 (0.58) | CXCR4CAPN1CTSB | |
| SCHEMBL30467090 | 0.90 | CAPN1 (0.52) | CXCR4GNRHRCAPN1CTSBCXCL8 | |
| SCHEMBL31058453 | 0.89 | GLP1R (0.55) | — | |
| SCHEMBL31241397 | 0.89 | DPP3 (0.51) | CXCR4CAPN1CTSBCXCL8 | |
| SCHEMBL31058456 | 0.88 | C5AR1 (0.56) | — | |
| SCHEMBL29616500 | 0.87 | CXCR4 (0.61) | CXCR4 | |
| SCHEMBL30608594 | 0.86 | CAPN1 (0.54) | CXCR4CAPN1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055154-A1 | LONG-ACTING DUAL-AGONIST COMPOUND | CHENGDU AODA BIOTECHNOLOGY CO LTD (CN) | 2026-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055154-A1 | LONG-ACTING DUAL-AGONIST COMPOUND | GIPR, GLP1R, GCG | CXCR4 2521/4885GNRHR 381/4885CAPN1 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.